code
stringlengths 7
7
| procedure
stringlengths 8
198
|
|---|---|
XRH83FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 8 or more Thoracic Vertebral Joints, Percutaneous Approach, New Technology Group 10 |
XRH84FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 8 or more Thoracic Vertebral Joints, Percutaneous Endoscopic Approach, New Technology Group 10 |
XRHA0FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Thoracolumbar Vertebral Joint, Open Approach, New Technology Group 10 |
XRHA3FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Thoracolumbar Vertebral Joint, Percutaneous Approach, New Technology Group 10 |
XRHA4FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Thoracolumbar Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 10 |
XRHB018 | Insertion of Posterior Spinal Motion Preservation Device into Lumbar Vertebral Joint, Open Approach, New Technology Group 8 |
XRHB0FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbar Vertebral Joint, Open Approach, New Technology Group 10 |
XRHB3FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbar Vertebral Joint, Percutaneous Approach, New Technology Group 10 |
XRHB4FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbar Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 10 |
XRHC0FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 2 or more Lumbar Vertebral Joints, Open Approach, New Technology Group 10 |
XRHC3FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 2 or more Lumbar Vertebral Joints, Percutaneous Approach, New Technology Group 10 |
XRHC4FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into 2 or more Lumbar Vertebral Joints, Percutaneous Endoscopic Approach, New Technology Group 10 |
XRHD018 | Insertion of Posterior Spinal Motion Preservation Device into Lumbosacral Joint, Open Approach, New Technology Group 8 |
XRHD0FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Open Approach, New Technology Group 10 |
XRHD3FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Percutaneous Approach, New Technology Group 10 |
XRHD4FA | Insertion of Pedicle Based Carbon/PEEK Spinal Stabilization Device into Lumbosacral Joint, Percutaneous Endoscopic Approach, New Technology Group 10 |
XRRG0L8 | Replacement of Right Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8 |
XRRG0M8 | Replacement of Right Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8 |
XRRH0L8 | Replacement of Left Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8 |
XRRH0M8 | Replacement of Left Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8 |
XT25XE5 | Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology Group 5 |
XW00X27 | Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 |
XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 |
XW01329 | Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 |
XW0136A | Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 |
XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013L9 | Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
XW013S6 | Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013S9 | Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 |
XW013T6 | Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013U6 | Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 |
XW013V7 | Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
XW013W5 | Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
XW013W7 | Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
XW01X27 | Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7 |
XW020D8 | Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8 |
XW023S6 | Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6 |
XW023T6 | Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6 |
XW023U6 | Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6 |
XW023V7 | Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7 |
XW023W7 | Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7 |
XW023X7 | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
XW023Y7 | Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
XW03306 | Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW03308 | Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW03326 | Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW03336 | Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW0333A | Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW0334A | Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW03357 | Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW03358 | Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0335A | Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW03366 | Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW03367 | Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW03368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW03372 | Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2 |
XW03377 | Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW03378 | Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW03387 | Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW03388 | Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0338A | Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW03396 | Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW03398 | Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
XW0339A | Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033A6 | Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033A7 | Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033B3 | Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3 |
XW033B6 | Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033B7 | Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033BA | Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033C6 | Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033CA | Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033D6 | Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033DA | Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033E5 | Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033E6 | Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033F3 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3 |
XW033F5 | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033F6 | Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033FA | Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
XW033G5 | Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033G6 | Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033H5 | Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5 |
XW033H6 | Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033J7 | Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033K7 | Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033K9 | Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |
XW033L6 | Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6 |
XW033L7 | Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033M7 | Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033N7 | Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
XW033P9 | Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9 |